April 26, 2012
Dainippon Sumitomo Pharma (DSP) announced on April 24 that its atypical antipsychotic Latuda (lurasidone HCl) demonstrated usefulness for bipolar I depression in two PIII clinical trials. The drug showed statistically significant differences to placebo in primary endpoints and key secondary...read more